These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34302278)

  • 21. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.
    Thorne K; Alrubaiy L; Akbari A; Samuel DG; Morrison-Rees S; Roberts SE
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):369-82. PubMed ID: 26825217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological agents in ulcerative colitis. When to prescribe].
    Barreiro-de Acosta M
    Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():36-42. PubMed ID: 25443225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
    García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
    J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel application of infliximab for diversion colitis.
    Kido M; Tamura R; Yasui Y; Okajima H
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34598959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.
    Monterubbianesi R; Aratari A; Armuzzi A; Daperno M; Biancone L; Cappello M; Annese V; Riegler G; Orlando A; Viscido A; Meucci G; Gasbarrini A; Guidi L; Lavagna A; Sostegni R; Onali S; Papi C; Kohn A;
    J Crohns Colitis; 2014 Aug; 8(8):852-8. PubMed ID: 24472490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection.
    Kin C; Kate Bundorf M
    J Gastrointest Surg; 2017 Jul; 21(7):1159-1165. PubMed ID: 28484890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.
    Moore SE; McGrail KM; Peterson S; Raval MJ; Karimuddin AA; Phang PT; Bressler B; Brown CJ
    Dis Colon Rectum; 2014 Jan; 57(1):83-90. PubMed ID: 24316950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center.
    Govani SM; Berinstein JA; Waljee AK; Stidham RW; Higgins PDR; Hardiman KM
    Dig Dis Sci; 2020 Jun; 65(6):1800-1805. PubMed ID: 31748921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
    Volonaki E; Mutalib M; Kiparissi F; Shah N; Lindley KJ; Elawad M
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1425-8. PubMed ID: 26426835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.
    Filippi J; Allen PB; Hébuterne X; Peyrin-Biroulet L
    Curr Drug Targets; 2011 Sep; 12(10):1440-7. PubMed ID: 21466486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
    Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
    Dig Liver Dis; 2002 Sep; 34(9):626-30. PubMed ID: 12405248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Features and Therapeutic Outcomes of Post-colectomy Enteritis with Ulcerative Colitis.
    Horio Y; Uchino M; Hori K; Kusunoki K; Minagawa T; Kuwahara R; Kataoka K; Beppu N; Ikeda M; Ikeuchi H
    J Anus Rectum Colon; 2021; 5(4):405-413. PubMed ID: 34746505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.